Evidence map›Paper›PMID 34242791›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2021

Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma.

Beow Y Yeap, Assunta De Rienzo, Ritu R Gill, Michela E Oster, Mary N Dao, Nhien T Dao, Rachel D Levy, Kimberly Vermilya, Corinne E Gustafson, Gavin Ovsak and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. An Evaluation Into the Robustness of Grading of Pleural Mesothelioma Outside of Specialist Centres.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Beow Y YeapDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Assunta De RienzoThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Ritu R GillDepartment of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Michela E OsterThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Mary N DaoThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Nhien T DaoThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Present Address: Takeda, Cambridge, Massachusetts.
Rachel D LevyThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Kimberly VermilyaThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Corinne E GustafsonThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Gavin OvsakDepartment of Anesthesia, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
William G RichardsThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Raphael BuenoThoracic Surgery Oncology Laboratory and International Mesothelioma Program (www.impmeso.org), Division of Thoracic and Cardiac Surgery and The Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: rbueno@bwh.harvard.edu.
Brigham and Women's Hospital · USBeth Israel Deaconess Medical Center · USHarvard University · US

Funding

Validation of Prognostic and Diagnostic Molecular Tests in MesotheliomaR01CA120528 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUENO, RAPHAEL · 2006 to 2021
$4.8M
NCI NIH HHS R01 CA120528
6 · The paper itself

Abstract

introductionPrognostic models for malignant pleural mesothelioma have been limited to demographics, symptoms, and laboratory values. We hypothesize higher accuracy using both tumor and patient characteristics. The mesothelioma prognostic test (MPT) and molecular subtype based on claudin-15-to-vimentin expression ratio are molecular signatures associated with survival. Tumor volume (TV) has improved performance compared with clinical staging, whereas neutrophil-to-lymphocyte ratio (NLR) is prognostic for malignant pleural mesothelioma.

methodsTumor specimens and clinical data were collected prospectively from patients who underwent extrapleural pneumonectomy (EPP) or pleurectomy and decortication (PD) during 2007 to 2014. MPT and claudin-15-to-vimentin ratio were determined by real-time quantitative polymerase chain reaction, whereas TV was assessed from preoperative scans. Risk groups were derived from combinations of adverse factors on the basis of the Cox model. Predictive accuracy was assessed using Harrell's c-index.

resultsMPT, molecular subtype, TV, and NLR were independently prognostic in patients with EPP (N = 191), suggesting equal weighting in a final three-group model (c = 0.644). In the PD cohort (N = 193), MPT poor risk combined with TV greater than 200 cm

conclusionsThe novel models use pretreatment parameters obtained from minimally invasive biopsy, imaging, and blood tests to evaluate the expected outcome of each type of surgery in newly diagnosed patients and improve stratification on clinical trials.

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsAlgorithmsHumansNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesRisk FactorsMesotheliomaPredictionRT-qPCR testsSurgerySurvival

Identifiers

PMID34242791
PMCPMC8557128
OpenAlexW3178152428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.